Ksilink proudly takes part of the EC funded EnvironMENTAL consortium. Want to know more? You are invited to join a series of seminars! EnvironMENTAL aims at identifying the...
Ksilink engaged in EnvironMENTAL
read more
Patient-based drug discovery's latest news
First success for Personalized Functional Profiling (PFP) of gastro-intestinal cancers
Ksilink proudly announces the publication of exciting results in the journal “Cancer Biology & Therapy”. In fact, the technology for Personalized Functional Profiling (PFP) of...
Journée de l’amitié franco-allemande/Tag der deutsch-französischen Freundschaft
A l'occasion de la journée de l'amitié franco-allemande, Ksilink vous présente ses meilleurs vœux pour l'année 2022 ! Version française Anlässlich des Tages der...
Ksilink wishes you all the best for 2022!
What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological...
The ANR supports our efforts in drug discovery for Myotonic Dystrophy type 1
Ksilink is happy to announce the initiation of the ANR funded project "Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)". This project is supporting...
New solutions to treat Rubinstein-Taybi
Ksilink is happy to have welcomed the team of Prof. Valérie Mezger-Lallemand from Université Didérot to initiate a collaboration with the aim to establish a new patient-based disease model to identify …
AI-powered Drug Discovery symposium
We are proud to be present with two posters during the AI powered Drug Discovery Symposium from 8-9th of November 2021 in London, at Francis Crick Institute. Download our poster...
We are proud to announce the release of our new website!
We are happy to welcome you on our new website. We will keep you informed about news and activities around patient-based drug discovery. Come and visit us on www.ksilink.com !!
Virtual tour I-Stem
Ksilink is pleased to share with you this virtual tour of its partner CECS I-Stem with the following message of its founder and scientific director Marc Peschanski: “Dear...